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Abstract
Fanconi anemia (FA) is a rare bone marrow failure disorder characterized by
clinical and genetic heterogeneity with at least 17 genes involved, which make
molecular diagnosis complex and time-consuming. Since next-generation
sequencing technologies could greatly improve the genetic testing in FA, we
sequenced DNA samples with known and unknown mutant alleles using the
Ion PGMTM system (IPGM). The molecular target of 74.2 kb in size covered
96% of the FA-coding exons and their flanking regions. Quality control testing
revealed high coverage. Comparing the IPGM and Sanger sequencing output of
FANCA, FANCC, and FANCG we found no false-positive and a few false-nega-
tive variants, which led to high sensitivity (95.58%) and specificity (100%) at
least for these two most frequently mutated genes. The analysis also identified
novel mutant alleles, including those in rare complementation groups FANCF
and FANCL. Moreover, quantitative evaluation allowed us to characterize large
intragenic deletions of FANCA and FANCD2, suggesting that IPGM is suitable
for identification of not only point mutations but also copy number variations.
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Introduction
Fanconi anemia (FA) is an autosomal or X-linked reces-
sive bone marrow failure disease associated with congeni-
tal malformations and increased risk of developing
hematological and solid tumors (Kee and D’Andrea
2012). FA is caused by mutations in at least 17 genes,
(Bogliolo et al. 2013; Kottemann and Smogorzewska
2013; Sawyer et al. 2015), three [FANCA (OMIM
607139), FANCC (OMIM 613899), and FANCG (OMIM
602956)] of which account for ~80% of the FA cases.
Except for a few founder effects in specific populations,
there is a wide spectrum of private mutations, including
large intragenic deletions (The Rockefeller University.
Fanconi Anemia database, http://www.rockefeller.edu/
fanconi/).
The genetic heterogeneity together with the numerous
mutations that affect the FA genes makes molecular
diagnosis complex. It is a tiered process starting from
clinical suspicion that is then confirmed at the cellular
level, testing sensitivity of patient’s cells to DNA inter-
strand cross-linking agents, such as diepoxybutane (DEB
test) (Auerbach 1993). If the DEB test is positive, identifi-
cation of mutations is fundamental for a correct manage-
ment of patients in terms of genetic counseling, carrier
testing, and prenatal diagnosis. An inconclusive DEB test
might occur in patients with hematopoietic mosaicism
arising from spontaneous genetic events, such as back
mutations, leading to reversion of the FA cellular pheno-
type (Waisfisz et al. 1999; Gross et al. 2002).
Without any knowledge on candidate genes, molecular
genetic testing usually starts from FANCA, which is
mutated in 60–80% of FA families (Castella et al. 2011; De
Rocco et al. 2014). The analysis consists of Sanger sequenc-
ing of 43 coding exons combined with MLPA (Multiple
Ligation-dependent Probe Amplification), being almost
20% of the FANCA alleles characterized by large intragenic
deletions due to numerous Alu repeats localized within its
intronic regions (Morgan et al. 1999). If no FANCA muta-
tion is identified, the screening is extended to the other FA
genes. Alternatively, the candidate gene can be identified by
complementation analysis or restricted to components of
the FA pathway playing a role up- or down-stream of
FANCD2 (OMIM 613984) on the basis of its monoubiqui-
tination status (Bogliolo et al. 2013; Kottemann and Smog-
orzewska 2013; Sawyer et al. 2015).
Whatever is the procedure, identifying FA mutations is
expensive and time-consuming. The analysis would
greatly benefit from application of next-generation
sequencing (NGS) technologies, such as the Ion PGMTM
(IPGM; Life Technologies) platform. This technology was
applied to 28 FA patients and allowed us to identify 45
FA mutant alleles, including seven large intragenic dele-
tions of FANCA, suggesting that the IPGM sequencer well
responds to the requirements for the screening of the FA
genes.
Methods
Biological samples
Thirty DNA samples (14 males and 16 females), 28 from
FA probands with positive DEB test and two from healthy
controls, were analyzed in this study (Table 1). All the
subjects or their legal guardians gave written informed
consent to the investigation, according to the Declaration
of Helsinki. DNA samples were isolated from peripheral
blood (n = 25) or from lymphoblastoid cell lines (n = 5)
using a High Pure PCR Template Preparation Kit (Roche,
Indianapolis, USA). In 25 samples, at least one of the
most frequently mutated genes (FANCA, FANCC or
FANCG) was previously analyzed by Sanger sequencing
(De Rocco et al. 2014). Of the 28 affected individuals,
both FA alleles were characterized in 15 cases. In three
cases, including two with hematopoietic mosaicism
(Waisfisz et al. 1999), only one FA allele was identified.
In this cohort, 23 FA alleles were still missing. All samples
were tested using the Salsa MLPA kit with probe mix
P031/P032 according to the manufacture protocol (MRC-
Holland, Amsterdam, the Netherlands). Reactions were
run on ABI PRISM 3130 Genetic Analyzer (Applied
Biosystems, Foster City, CA), and analyzed by Gene Map-
per version 3.2 and MRC-Holland Coffalyzer software.
IPGM sequencing
The IPGM sequencing was carried out according to the
manufacture’s protocols (Life Technologies, Carlsbad, CA).
The following FA genes were targeted: FANCA (GenBank
NM_000135.2), FANCB (OMIM 300515; GenBank
NM_001018113.1), FANCC (GenBank NM_000136.2),
BRCA2 (FANCD1; OMIM 600185; GenBank
NM_000059.3), FANCD2 (GenBank NM_001018115.1),
FANCE (OMIM 613976; GenBank NM_021922.2), FANCF
(OMIM 613897; GenBank NM_022725.3), FANCG (Gen-
Bank NM_004629.1), FANCI (OMIM 611360; GenBank
NM_001113378.1), BRIP1 (FANCJ; OMIM 605882; Gen-
Bank NM_032043.2), FANCL (OMIM 608111; GenBank
NM_018062.3), FANCM (OMIM 609644; GenBank
NM_020937.2), PALB2 (FANCN; OMIM 610355; GenBank
NM_024675.3), RAD51C (FANCO; OMIM 602774; Gen-
Bank NM_058216.2), SLX4 (FANCP; OMIM 613278; Gen-
Bank NM_032444.2), ERCC4 (FANCQ; OMIM 133520;
GenBank XM_011522424.1). The BRCA1 (FANCS; OMIM
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Table 1. Features of DNA samples included in the study.
DNA
sample
ID Gender
DNA
sample
source1
FANC genes
analyzed by
Sanger
sequencing
Mutant
gene
Mutations identified
by Sanger sequencing2
Mutations identified
by Ion PGMTM2 Reference
W1 M PBC A, G Wild type None None This paper
W2 F PBC A, C, G Wild type None [c.50C>G, p.(Pro17Arg) in FANCL] This paper
P3 M PBC A FANCA c.3558dup
p.(Arg1187Glufs*28)
Excluded from all analyses De Rocco et al.
(2014) (FA29)
c.1360-?_2778+?del
p.(Ala454_His926del)
(del ex15_28)
P4 F PBC A FANCA c.1360-?_1470+?del
p.(Ala454_Gln490del)
(del ex15)
Excluded from CNV analysis De Rocco et al.
(2014) (FA40)
c.894-?_3348+?del
p.(Trp298*)
(del ex11_33)
P5 M PBC A FANCA c.3788_3790del
p.(Phe1263del)
Confirmed De Rocco et al.
(2014) (FA1)
c.3788_3790del
p.(Phe1263del)
P6 F PBC A FANCA c.3239G>A
p.(Arg1080Gln)
Confirmed De Rocco et al.
(2014) (FA10)
c.3971C>T
p.(Pro1324Leu)
P7 M PBC A FANCA c.457C>T
p.(Gln153*)
Confirmed
[c.1466T>C, p.(Ile489Thr) in
FANCJ and c.1249G>T,
p.(Glu417*) in FANCM]
De Rocco et al.
(2014) (FA13)
c.709+1G>A
P8 M PBC A FANCA c.3788_3790del
p.(Phe1263del)
Confirmed
[c.1096_1099dup,
p.(Thr367Asnfs*13) in FANCL]
De Rocco et al.
(2014) (FA21)
c.3971C>T
p.(Pro1324Leu)
P9 F PBC A FANCA c.2638C>T
p.(Arg880*)
Confirmed
[c.-78-?_5024+?del
(del ex1_44) in FANCD2]
De Rocco et al.
(2014) (FA37)
c.3164G>A
p.(Arg1055Gln)
P10 F LCL A FANCA c.3638_3639del
p.(Pro1213Argfs*64)
Confirmed De Rocco et al.
(2014) (FA42)
c.3971C>T
p.(Pro1324Leu)
P11 F LCL A FANCA c.3761_3762dup
p.(Glu1255Argfs*12)
False negative3 De Rocco et al.
(2014) (FA43)
c.2574C>G
p.(Ser858Arg)
Confirmed
[c.2204G>A, p.(Arg735Gln)
in FANCD2]
P12 M PBC A FANCA c.2290C>T
p.(Arg764Trp)
Confirmed De Rocco et al.
(2014) (FA44)
c.4029T>G
p.(His1343Gln)
P134 M PBC A FANCA c.1450G>C
p.(Glu484Gln)
Confirmed This paper
Not found Not found
P14 M PBC A, G FANCA c.1115_1118del
p.(Val372Alafs*42)
Confirmed De Rocco et al.
(2014) (FA85)
c.1126C>T
p.(Gln376*)
(Continued)
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Table 1. Continued.
DNA
sample
ID Gender
DNA
sample
source1
FANC genes
analyzed by
Sanger
sequencing
Mutant
gene
Mutations identified
by Sanger sequencing2
Mutations identified
by Ion PGMTM2 Reference
P15 M PBC A FANCA c.2812_2830dup
p.(Asp944Glyfs*5)
Confirmed De Rocco et al.
(2014) (FA20)
c.-42-?_5481+?del (del ex1_43)
P16 M PBC A FANCA c.1850_1859del
p.(Leu617Profs*20)
Confirmed De Rocco et al.
(2014) (FA67)
c.1827-?_2778+?del
p.(Arg609Serfs*2)
(del ex21_28)
P17 F PBC A FANCA c.457C>G
p.(Gln153Glu)
Confirmed
[c.2816T>G,
p.(Leu939Trp) in FANCN]
De Rocco et al.
(2014) (FA65)
c.3490C>T
p.(Pro1164Ser)
c.1471-?_1626+?del
p.(Val491_Glu542del)
(del ex16_17)
P18 F PBC A, C, G FANCA c.893+5G>A
p.(Phe879Valfs*19)
Confirmed
[c.1151C>T,
p.(Ser384Phe) in FANCD1]
De Rocco et al.
(2014) (FA28)
c.190-?_283+?del
p.(Val64Alafs*43)
(del ex3)
P195 F PBC A, G FANCA c.1360-?_1826+?del
p.(Ala454Serfs*3)
(del ex15_20)
Confirmed De Rocco et al.
(2014) (FA61)
Not found Not found
P206 M PBC A, C, G FANCA c.4258G>T
p.(Glu1420*)
Confirmed
[c.874C>G, p.(Pro292Ala)
and c.5848T>G,
p.(Leu1950Val) in FANCM]
De Rocco et al.
(2014) (FA41)
Not found Not found
P21 F PBC A, G FANCC Not found c.67del
p.(Asp23Ilefs*23)
De Rocco et al.
(2014) (FA88)
c.67del
p.(Asp23Ilefs*23)
P22 F LCL A, G FANCC Not found c.37C>T
p.(Gln13*)
De Rocco et al.
(2014) (FA89)
c.692_694del
p.(Lys231del)
P23 F PBC A, G FANCC Not found c.37C>T
p.(Gln13*)
This paper
c.1069C>T
p.(Gln357*)
[c.9875C>T,
p.(Pro3292Leu) in FANCD1]
P24 F LCL G FANCF Not found c.484_485del
p.(Leu162Aspfs*103)
This paper
c.484_485del
p.(Leu162Aspfs*103)
P25 M PBC A, G Not found Not found Not found This paper
P26 M PBC None FANCA nd c.3788_3790del
p.(Phe1263del)
De Rocco et al.
(2014) (FA58)
c.826+3del
p.(250_251insGlyAlaPhe
MetThrArgCysGlyPheLeu)
(Continued)
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113705) was not included in the analysis because of its
recent identification (Sawyer et al. 2015).
Briefly, to sequence the coding exons and their flanking
regions of the 16 FA genes primers were designed using
the Ion Ampliseq Designer software (Life Technologies,
Carlsbad, CA, https://www.ampliseq.com/browse.action)
and divided in two pools. Libraries were prepared using
Ion Ampliseq library kit 2.0. Template were enriched in
the Ion One Touch 2 system (Ion PGM template OT2
200 kit) and sequenced on IPGM sequencer (IPGM
Sequencing 200 Kit v2). In order to assure high coverage,
12 libraries (6 DNA samples) were loaded into 316 chips.
For quality evaluation and alignment to the hg19 human
genomic sequence, sequencing data were analyzed using
the Ion Torrent Suite software’s plug-ins (Lifetechnolo-
gies, Carlsbad, CA) Coverage Analysis (TSCA, v4.0) and
Variant caller (TSVC, v.4.0). Functional annotation was
performed using the w-annovar software (http://wann-
ovar.usc.edu/). Libraries alignment was visualized using
Integrative Genomics Viewer (IGV) software (Thorv-
aldsdottir et al. 2013). To confirm variants, Sanger
sequencing was carried out on FA exons as previously
described (De Rocco et al. 2014).
Detection of CNV
Statistical analyses for detection of copy number varia-
tions (CNV) implied two normalizations for each sample.
Table 1. Continued.
DNA
sample
ID Gender
DNA
sample
source1
FANC genes
analyzed by
Sanger
sequencing
Mutant
gene
Mutations identified
by Sanger sequencing2
Mutations identified
by Ion PGMTM2 Reference
P27 F PBC None FANCA nd c.1776+7A>G
p.(Ile573Serfs*12)
De Rocco et al.
(2014) (FA66)
c.1827-?_2852+?del
p.(Ala610_Arg951del)
(del ex21_29)
P28 F PBC None FANCA nd c.548G>A
p.(Trp183*)7
De Rocco et al.
(2014) (FA49)
c.523-?_2981+?del
p.(Ser175Leufs*5)
(del ex6_30)
P29 F PBC None FANCA nd c.3660del
p.(Asn1221Thrfs*26)
De Rocco et al.
(2014) (FA47)
c.50dup
p.(Arg18Profs*19)7
P30 M LCL None FANCL nd c.50C>G
p.(Pro17Arg)
This paper
c.676C>T
p.(Arg226Cys)
c.1021T>A
p.(Trp341Arg)
1PBC, peripheral blood cells; LCL, lymphoblast cell line.
2Nucleotide A of the ATG translation initiation start site of the FANCA, FANCC, FANCD1, FANCD2, FANCF, FANCG, FANCJ, FANCL, FANCM, and
FANCN cDNAs from GenBank sequences NM_000135.2, NM_000136.2, NM_000059.3, NM_001018115.1, NM_022725.3, NM_004629.1,
NM_032043.2, NM_018062.3, NM_020937.2, and NM_024675.3, respectively is indicated as nucleotide +1. In square brackets are potential
pathogenetic heterozygous variants identified in genes different from that causing the disease. Large genomic deletions are indicated in bold.
3Mutation localized in a region where the reverse and forward primers of two adjacent amplicons aligned, reducing sequence efficiency of this
mutant allele. Mutation was not called by the TSVC because seen only 47 of 262 reads.
4Sib of patient FA70 in De Rocco et al. (2014). As FA 70, who was found to be a mosaic as the second mutant allele (c.596+1G>T) was identified
in fibroblast cells but not in LCL, P19 was enrolled as an FA patient with a potential hematopoietic mosaicism. For this reason, the second mutant
allele could be missed.
5Patient with potential hematopoietic mosaicism because of revertant lymphoblastoid cell line. Complementation analysis carried out in peripheral
blood T lymphocytes assigned this patient to FANCA genetic group but only one heterozygous mutation was identified. Due to the mosaic suspi-
cion, the second mutant allele could be missed.
6Potential hematopoietic mosaicism status was not ascertained in this patient, whose peripheral blood cells were the only biological sample
available.
7Identified by Sanger sequencing of uncovered amplicons.
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The first was an intrasample normalization, which was
calculated by dividing the total number of reads of each
amplicon by the total reads average obtained from the
same library. Since almost 20% of the FANCA alleles are
large intragenic deletions and FANCB is localized on
chromosome X (Morgan et al. 1999), we excluded the
FANCA and FANCB amplicons from the calculation of
the total reads of each library. The second was an inters-
ample normalization, which was determined by dividing
the intrasample normalization of each amplicon by the
average of all the intrasample normalization of this ampli-
con from control samples. As control samples in the in-
tersample normalization of FANCA and FANCB
amplicons, we used data from 21 samples without FAN-
CA deletions (from MLPA analysis) and from 15 females,
respectively. For the intrasample normalization of ampli-
cons of the other FA genes, we use all the samples
(n = 28) except for P3 and P4, which had the lowest
uniformity amplicon coverage. All those amplicons that
did not achieve the threshold of 309 in more than three
samples were excluded from the analysis.
We considered intersample normalization ratios lower
than 0.7 indicative of heterozygous deletions and ratios
higher than 1.3 suggestive of duplications. Graphs were
performed using the software Minitab Statistical Soft-
ware (version 16, Minitab INC., State College, Pennsylva-
nia). Statistical analyses were performed using the
statistical software Minitab (version 16). Median and in-
terquartile range (IQR) were used to described nonnor-
mal distribution data, whose comparison was performed
by the Mann–Whitney test.
Results
IPGM sequencing quality: high coverage for
95% of amplicons
The FA genes represented a target of 74.2 kb split into
693 amplicons ranging in size from 125 to 225 bp. The
amplicons cover 96% of the coding exon sequences with
~30 bp of their flanking intronic sequences. The regions
excluded by the design (4%) are variably dispersed
through all the genes, varying from 0.03% (FANCQ) to
10% (FANCE) of the targeted sequences (data not
shown). All samples satisfied the quality control parame-
ters except for P3, a partially degraded DNA that was
excluded from further analysis because the uniformity of
amplicon coverage was below 50% (Table S1).
Coverage analysis found that 35 of the 693 amplicons
did not reach the threshold of 309 in at least one of the
samples (Table S2). Five amplicons were not covered in at
least 10 samples, suggesting that “constitutive” features of
DNA could be responsible for the low sequencing effi-
ciency. It is reasonable to hypothesize that repetitive
sequences or primer self-annealing interfere with amplifica-
tion rate. For instance amplicon AMPL544050257 (exon 1
of FANCA), which is a GC-rich region (78%), did not
reach the threshold of 309 in 15 samples. For amplicons
AMPL1197148282 (exon 4 of FANCB), AMPL404630568
and AMPL388340296 (exons 11 and 20 of FANCD1), and
AMPL433543078 (exon 17 of FANCJ) the coverage was less
than 309 in 12, 10, 21, 15 samples, respectively, more likely
because of self-annealing or intra-strand loop formation of
primers, as revealed by inspection of primer sequences. For
the remaining 30 amplicons the coverage was less than 309
in 1–7 samples, indicating the presence of “occasional”
interfering factors (Table S2). The two amplicons covering
exon 15 of FANCA were not sequenced in P4, which carried
two large heterozygous deletions encompassing this exon
(Table 1). In P28, a compound heterozygote for the c.523-?
_2981+?del and c.548G>A mutations of FANCA, amplicon
AMPL544193477 (exon 6) was not covered because deleted
on one allele and not amplified on the other for the pres-
ence of c.548G>A in one of the primer complementary
sequence. Inspection of the other uncovered amplicons did
not provide us with any insight into the potential mecha-
nisms of their low coverage. It is likely that allelic drop-out
for the presence of rare variants is involved.
High sensitivity and specificity of IPGM
sequencing for FANCA, FANCC, and FANCG
After sequencing quality evaluation, we determined
whether the variants called in the 29 samples were true
(TPs) or false positives (FPs). Of the 2005 annotations
(~70 per sample), we selected those (n = 173; 48 different)
that were located in the genomic regions of the FANCA,
FANCC, and FANCG genes that were previously screened
by Sanger sequencing (208,001 nt) (Fig. 1). Comparing
data from the two technologies, we found that all the 173
variants were TPs because also detected by Sanger
sequencing. Among these, 23 were known mutations of
FANCA (Table 1). Of note, no FPs was annotated. In the
same regions, however, the IPGM sequencing did not call
eight false-negative variants (FNs; 6 different), one of
which was the heterozygous c.3761_3762dup mutation
(FANCA) identified in sample P11. This duplication was
likely to have not been called because of allelic drop-out
being located in exon 37 where the reverse and forward
primers of the two adjacent amplicons aligned.
Using these data (TP = 173, FP = 0, and FN = 8) and
considering the number of true negative (TN;
N = 207,820), we calculated sensitivity [TP/(TP + FN)]
and specificity [TN/(TN + FP)] that, at least for the
FANCA, FANCC, and FANCG genes, were 95.58% and
100%, respectively (Fig. 1).
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Characterization of novel FA alleles
In addition to these 173 TPs, the IPGM sequencing called
another 1832 variants (Fig. 1), some of which were
expected to be the mutations yet uncharacterized in our
cohort (23 alleles) (Table 1). We selected those (N = 171)
with minor allele frequency (MAF) <0.01, as derived from
dbSNP database. Screening the genomic regions contain-
ing these variants by Sanger sequencing (36,299 nt;
Fig. 1), we could analyze 36 additional annotations that
were previously excluded because of their MAF > 0.01.
Of these 207 variants, 83 (67 different) were TPs and 124
(19 different) FPs.
Among the 67 different TPs (Table S3), we searched
for known FA mutations and/or deleterious variants,
such as nonsense and frameshift mutations, amino acid
substitutions with high pathogenetic prediction, and
putative alternative splicing variants (Table S3). This
allowed us to characterize 13 mutant alleles of FANCA,
FANCC, and FANCF in eight (P21, P22, P23, P24, P26,
P27, P28, and P29) of the 10 samples without any FA
mutations (Table 1). In sample P30, we identified three
different missense mutations (p.Pro17Arg, p.Arg226Cys,
and p.Trp341Arg) in FANCL, whose pathogenetic effect
has been demonstrated by complementation analysis (De
Rocco and Hanenberg, unpubl. ms.). Of interest, one het-
erozygous pathogenetic variant of FANCL (p.Pro17Arg)
was also confirmed by Sanger sequencing in control sample
W2 (Table 1). The remaining TPs were heterozygous vari-
ants, most of which reported in the dbSNP database. They
mainly affect intronic regions outside the consensus splice
site sequences, though five were expected to create cryptic
splice sites (Table S3). Others were synonymous or benign
missense variants, as determined by bioinformatics tools.
However, nine were expected to be pathogenetic. They were
seven missense mutations of FANCD1, FANCD2, FANCJ,
FANCM, and FANCN, one frameshift (p.Thr367Asnfs*13)
and one nonsense (p.Glu417*) mutations of FANCL and
FANCM, respectively (Tables 1; S3).
In this analysis, 124 FPs were also annotated (Table
S4). Most of the 19 different FPs were localized in homo-
polymeric regions (Bragg et al. 2013). Of note, four were
called in more than 22 patients, suggesting that they
could be filtered in a standardized diagnostic workflow.
Identification of FA CNV: correct assignment
of gender
To understand whether the IPGM data could be used for
CNVs detection, we determined whether the analysis of
FANCB, the only FA gene located on chromosome X,
could allow us to distinguish male from female individu-
als. Consistent with our knowledge on gender, all males
had median and IQR below 0.7, which is indicative of
hemizygosity condition (Fig. 2). In females, whereas the
median always ranged between 0.7 and 1.3, the box plots
extended out of the normal range in four cases (P4, P17,
P22, and P23). Whereas in P17, P22, and P23 the upper
value of IQR was just above the threshold of 1.3, in P4
the attribution of gender was instead ambiguous as the
IQR ranged from 0.27 to 1.31 (Fig. 2). Although we can-
not exclude a partial deletion of FANCB, sample P4 was
Figure 1. Schematic representation of the
study. The IPGM sequencing output underwent
a quality control process and analysis of the
amplicon coverage data to detect CNVs. Of
the 2005 variants called by IPGM, 173 were
localized in regions (208,001 nt) of FANCA,
FANCC, and FANCG that were previously
analyzed by Sanger sequencing. All were TP.
Although no FP variants were called, IPGM did
not detected eight FN. Of the remaining 1832
variants, only those (N = 171) with a
MAF < 0.01 were taken into consideration.
Sanger sequencing of regions containing these
variants tested another 36 variants (N = 207
total variants) and identified 83 TP and 124 FP.
IPGM, Ion PGMTM; CNV, copy number
variations; TP, true positive; FP, false-positive;
FN, false negative; MAF, minor allele
frequency; TN, true negative.
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excluded from the CNV analysis because of its relatively
low uniformity index (Table S1). The differences observed
between males and females were not due to random
variations of the FANCB coverage in almost all cases
(Table S5).
Deletions of the entire FANCA and FANCD2
genes
Using the same criteria as above, we determined whether
other FA genes were affected by CNVs. We found that the
median and IQR of the intersample normalization ratios in
FANCA and FANCD2 was significant lower than expected
in samples P15 and P9, respectively (Figs. 2 and S1). The
FANCA and FANCD2 deletions were confirmed by MLPA
and SNP array, respectively, showing that the both hemizy-
gous condition was extended to the entire gene (Figs. S2
and S3). Of note, since P9 was a compound heterozygous
with two mutant alleles of FANCA (Table 1), it would be
interesting to explore whether loss of function of FANCA
together with haploinsufficiency of FANCD2 makes the
phenotype worse. However, clinical data from this affected
individual are limited for any speculation.
Characterization of large intragenic
deletions of FANCA
In trying to detect partial deletions of FANCA, we first
used the IGV software and found that in samples with
known intragenic deletions the coverage of the deleted ex-
A
B
Figure 2. CNV analysis of the (A) FANCB and
(B) FANCA amplicons. The values were
represented by medians of intersample
normalization ratio and box plots reporting the
IQR. A median below 0.7 or between 0.7 and
1.3 is indicative of a single or double,
respectively copy of the gene. In the FANCB
box plot, the median is always below 0.7 and
between 0.7 and 1.3 in all the males (blue)
and females (pink), respectively. Even the IQR
respects the thresholds except for female
samples P4, P23, P17, and P22. Whereas in
P23, P17, and P22 the 3rd quartiles are just
above 1.3 (1.48, 1.34, and 1.41, respectively),
in P4 the IQR ranges from 0.27 to 1.31. For
this reason and for its low uniformity index
(Table S1), P4 was excluded from CNV
analysis. As determined by the Mann–Whitney
test, the differences observed between males
and females were not due to random
variations of the FANCB coverage (Table S5). In
the FANCA box plot, the mean is between 0.7
and 1.3 in all but one (P15) the samples. The
1st quartile was below 0.7 in P16 (0.67), P23
(0.58), P27 (0.66), and P28 (0.48), suggesting
potential intragenic deletions of FANCA. The
asterisks indicate the outliers. IQR, interquartile
range; CNV, copy number variations.
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Figure 3. Detection of large intragenic deletions in FANCA. IPGM and MLPA analysis of two novel deletions of exons 21–29 (P27) and exons 6–
30 (P28). Amplicons from the two IPGML1 and IPGML2 are reported in graphs showing hemizygous amplicons in red. MLPA output of two
probes mix (MLPAP031 and MLPAP032) from the Coffalayzer.net software, showing FANCA exons and reference loci (R) values. In both IPGM
and MLPA analysis, the intersample normalization of deleted adjacent exons is under the threshold of 0.7 (red line). IPGM, Ion PGMTM; MLPA,
multiple ligation-dependent probe amplification; IPGML, IPGM libraries.
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ons was reduced respect to that of the flanking undeleted
amplicons (data not shown). Then, a statistical evaluation
revealed that the first quartile of the coverage distribution
were below the threshold of 0.7 in P16 (IQR = 0.67–1.0),
P23 (IQR = 0.58–0.95), P27 (IQR = 0.66–1.09), and P28
(IQR = 0.48–1.01) (Fig. 2B). Considering that for small
deletions the intersample normalization ratios of ampli-
con coverage is likely to reside within the normal range,
we plotted the intersample normalization ratio of each
amplicon. In P16, P17, P18, and P19 we confirmed the
known CNVs (Table 1; Fig. S2). In P27 and P28 we iden-
tified two novel deletions encompassing exons 21–29 and
exons 6–30, respectively, which were confirmed by MLPA
analysis (Fig. 3). Despite its first quartile below threshold
0.7 (Fig. 2), amplicon plots and MLPA analysis did not
confirm any CNV in P23 (data not shown). Since in P23
the first quartile was below the threshold even for other
genes (Fig. S1), quality of this DNA sample could have
interfered with the coverage efficiency.
Uncharacterized FA alleles
Of the 23 FA alleles yet unknown in our cohort, the NGS
identified 14 point mutations and two large genomic
deletions. In order to characterize the seven missing vari-
ants, we carried out Sanger sequencing of all the uncov-
ered amplicons in P13, P19, P20, P25, P28, and P29
(Table S1), allowing us to identify the second mutant
FANCA allele, c.548G>A (exon 6) and c.50dup (exon 1),
in P28 and P29, respectively. In the remaining patients,
one (P13, P19, and P20) or two (P25) pathogenetic alleles
remained uncharacterized, suggesting that mutations out-
side of the target design or affecting novel FA genes are
involved (Castella et al. 2011).
Discussion
The extensive allelic and nonallelic genetic heterogeneity
of FA is one of the major problems in molecular diagnos-
tic testing of the disease. In recent years, various strate-
gies, mainly based on extensive screening of the FA genes
or complementation or protein analyses, have been devel-
oped to optimize mutation detection rate (Castella et al.
2011; De Rocco et al. 2014). In order to improve and
speed up this process, we evaluated the possibility to
apply NGS strategies to identify both point and CNV
alterations. The disease is caused by at least 17 different
genes, which explain FA in almost all the affected individ-
uals (Bogliolo et al. 2013; Kottemann and Smogorzewska
2013; Sawyer et al. 2015). Therefore, since only a small
portion of FA patients are likely to have mutations in
genes yet uncharacterized, we choose IPGM, a benchtop
sequencer for targeted sequencing that has successfully
been applied for mutational screening in tumors and
other monogenic diseases (Anasagasti et al. 2013; Balla
et al. 2014; Gu et al. 2014).
The 693 amplicons selected by the primer design soft-
ware covered 96% of the targeted regions consisting of
exons with their flanking regions of the FA genes.
Sequencing quality was relatively high with most of the
amplicons covered >309. The uniformity values ranged
from 87% to 98% in all but one (P3) the samples. Only a
relatively limited number (n = 35) of amplicons did not
reach the coverage threshold of 309 in a variable number
(from 1 to 21) of samples. Whereas in P3 the low unifor-
mity rate was likely to be due to low DNA quality, in the
other cases nucleotide inspection revealed high CG con-
tent of amplicons, sequences favoring dimer and hairpin
formation within oligonucleotides or SNPs leading to
allelic drop-out. However, the uncovered amplicons rep-
resented only 1% of the target regions, confirming high
efficiency of the primer design software. It is plausible
that designing new oligonucleotides, we would further
reduce the percentage of regions with low coverage.
Considering all the samples, the IPGM output called
2005 variants. Taking advantage of our previous Sanger
analyses (De Rocco et al. 2014), we compared the data
output from the same genomic regions of FANCA,
FANCC, and FANCG screened by the two techniques. In
these regions, all the variants annotated by IPGM
(n = 173 TPs) had also been detected by Sanger sequenc-
ing. Among these variants were the mutations accounting
for all but one the known FA alleles. The undetected
mutant allele (c.3761_3762dup in FANCA of P11) was
one of the eight FNs that was not called because of allelic
drop-out. Inspection of the other few FNs revealed that
they were mainly localized at the 50 and 30 ends of ampli-
cons, where the coverage drops reducing sequencing reli-
ability. If this takes place outside splice site regions, the
probability to miss pathogenetic mutations is strongly
reduced. However, amplicons are ~100 bp in size and lar-
ger exons are split into two or more amplicons with
primers designed in coding regions that may be hit by
mutations. If this occurs, as for c.3761_3762dup, pathoge-
netic variants could be missed. However, since we did not
reveal any FPs, sensitivity and specificity was 95.58% and
100%, respectively at least for the analysis of FANCA,
FANCC, and FANCG.
Among the other 1832 variants, we search for pathoge-
netic alterations to identify novel FA alleles. Since muta-
tions are rare variants, we selected those with
MAF < 0.01 (n = 171) for Sanger confirmation. Sequenc-
ing the relative exons, we could check another 36 variants
with MAF > 0.01. Of the 207 variants, 83 were TPs and
124 FPs. No FN emerged from this analysis, which cov-
ered more than 35,000 nt spread through all the FA genes
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of several individuals. As expected (Bragg et al. 2013), the
FPs were called in homopolymeric regions and some of
them were recurrent in many samples, suggesting that
some genomic regions are prone to FPs calling. Therefore,
it is of fundamental importance to annotate at least the
most frequent FPs for their systematic filtering.
Application of NGS is usually combined with MLPA or
microarray techniques in a comprehensive approach for
mutational screening. Large intragenic deletions are rela-
tively common in FA, as the FANCA locus has high con-
tent of Alu repeats that could generate intragenic CNVs
through unequal crossing-over (Morgan et al. 1999).
Indeed, massive parallel sequencing complemented with
array comparative genomic hybridization and RNA
sequencing analysis allowed the identification of biallelic
germline mutations in different FA families (Chandrase-
kharappa et al. 2013). However, it has been shown that
massively parallel sequencing techniques are feasible to
identify CNV in FA and other diseases (Ameziane et al.
2012; Grasso et al. 2015). Similarly, we used the amplicon
coverage data from IPGM to detect CNVs. First at all, we
discriminated between males and females using the cover-
age data of FANCB, the only FA gene localized on chro-
mosome X. Then, we confirmed five large deletions of
FANCA we previously identified by MLPA (De Rocco
et al. 2014). Moreover, we detected two novel heterozy-
gous large deletions of FANCA in patients P27 and P28,
which together with c.1776+7A>G and c.548G>A defined
the FANCA alleles in these two patients. Finally, as con-
firmed by SNP array the entire FANCD2 gene was deleted
in P9, a patient with biallelic mutations in FANCA.
Targeting all the FA genes, we might identify mutations
in more than one gene, as it occurred for P9 and another
seven patients. Whenever the number of patients is large
enough, it will be interesting to determine whether muta-
tions in more FA genes associate with more severe pheno-
types. Moreover, special attention should be paid to
variants of FANCM. Although is not regarded anymore as
an FA gene, it is a susceptibility gene for breast cancer
and individuals (P9 and P20) carrying some of its vari-
ants could be at risk of developing this malignancy (Kiiski
et al. 2014; Lim et al. 2014). Identification of mutations
in different genes could unveil puzzling questions about
correct assignment of the complementation group. The
recessive model of inheritance or complementation analy-
sis will help defining correctly the gene responsible for
the disease.
In summary, the IPGM technology allowed us to
obtain high-quality sequencing data. In 19 samples, both
mutant alleles were detected, including those in genes
that, such as FANCF and FANCL, are only rarely taken
into consideration in standard molecular diagnosis pro-
cess. Only one heterozygous mutation was instead
revealed in six individuals. In three of these patients, the
second allele was missed because located in a CG-rich
region (P29) or because of allelic drop-out (P11 and
P28). Considering that another two (P13 and P19) were
referred as potential hematopoietic mosaics and that a
mosaic condition could not be excluded in P20, back
mutations could have interfered with the detection of the
second mutation if present only in a small percentage of
reads. In these cases, DNA from different sources, such as
from primary skin fibroblast, would be useful for compre-
hensive molecular genetic testing. Finally, in the last sam-
ple (P25) we did not find any mutation; it is likely that a
novel FA gene is responsible for the disease in this
patient. Taken together these data indicate that IPGM is a
feasible platform for identifying mutations in the FA
genes according to a flow chart arisen from this study
(Fig. S4).
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Quality control data of 30 samples according to
IPGM analysis.
Table S2. Amplicons not covered more than 309.
Table S3. True positive (TP) variants identified during
characterization of novel FA alleles.
Table S4. False positive (FP) variants identified during
characterization of novel FA alleles.
Table S5. Mann-Whitney test between males and females.
Figure S1. CNV analysis of the FA genes. The analysis is
shown for all the FA genes except for FANCA and
FANCB (Fig. 1) in 28 of the 30 samples included in this
study (samples P3 and P24 have been excluded for their
low amplicon uniformity). Box plots report median, in-
terquartile range (IQR) and outliers (asterisks). A median
below 0.7 or between 0.7 and 1.3 (red and blue vertical
lines) is indicative of one or two copies, respectively of
the gene. The median is in the normal range for all sam-
ples except for P9 in FANCD2 and P23 in both FANCE
and FANCP. The 1st and the 3rd quartiles are low and
above the threshold of 0.7 and 1.3 in several samples, but
for most of which with only slight deviations. Of note,
FANCE and FANCF, the two genes covered by the lowest
number of amplicons (18 and 8, respectively), show IQR
deviations in a higher number of samples. Since in sample
P23 both median and IQR were outside the normal
ranges in eight genes without knowing the reasons, the
deviations were not considered reliable enough for sus-
pecting any CNV.
Figure S2. Detection of large intragenic known deletions
of FANCA. IPGM and MLPA analysis showing deletions
of the entire gene (P15), exons 21–28 (P16), exons 16–17
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(P17), exons 3 (P18), and exons 15–20 (P19). Amplicons
from the two IPGM libraries (IPGML1 and IPGML2) are
reported in graphs showing hemizygous amplicons in red.
MLPA output of two probes mix (MLPAP031 and
MLPAP032) from the Coffalayzer.net software, showing
FANCA exons and reference loci (R) values. In both
IPGM and MLPA analysis, the intersample normalization
of deleted adjacent exons is under the threshold of 0.7
(red line). Of note, in graph MLPAP031 of P15, the
apparent homozygous deletion of exon 29 is a false posi-
tive of MLPA because the mutation on the second allele
(c.2812_2830dup) is localized within the probe annealing
sequence of exon 29.
Figure S3. Graphical output for copy number using SNP-
based arrays on chromosome 3 in P9. The plot for the B
allele frequency shows a heterozygous deletion of 11.6 Mb
(235,748–11,880,816) on chromosome 3p26.3-p25.2 con-
taining the FANCD2 gene. In this patient the plot has
10% heterozygous (AB) SNP calls, as shown by the addi-
tional allele frequency, indicating a mosaicism of ~90%.
For probes that are normal copy number, the signal
intensity ratio of the subject versus controls is expected to
be 1, and log2 R ratio should be ~0.0 (log21 = 0). In the
other plot loss of copy number results in a negative log2
ratio of ~0.5. SNP array analysis was performed using
the Human OmniExpress-12 Bead Chip (Illumina Inc.,
San Diego, CA) according to Illumina’s Infinium HD
Assay protocol. Normalization of raw image intensity
data, genotype clustering and individual sample genotype
calls were performed using Illumina’s GenomeStudio soft-
ware v2011.1 (cnv partition 3.2.0). The CNV calls were
determined with generalized genotyping methods imple-
mented in the Penn CNV program.
Figure S4. Schematic representation of the molecular
diagnostic workflow that can be applied in FA using the
IPGM sequencing.
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